With the first pricing negotiation results of the Inflation Reduction Act now public, analysts will be diagnosing trends for commercial companies and the implications for their pipelines. Those pipeline effects will alter how large biopharma pursue M&A and collaborate with pre-commercial biotechs particularly regarding their small-molecule or biologic asset status, which will thereby adjust the risk profile for the venture community. Join this session to discuss how best to accommodate these trends in your own strategic planning.